Continuous variable modeling such as the Hodgkin lymphoma international prognostic index (A-HIPI) improves prognostic ...

Fixed-duration venetoclax regimens showed non-inferior progression-free survival compared to continuous ibrutinib in CLL ...

Families with children treated for ALL often face catastrophic financial toxicity, including severe income loss and inability to afford basic needs. Financial strain typically intensifies six months ...

Patients with polycythemia vera (PV) taking the investigational therapy rusfertide were able to largely maintain hematocrit control and avoid the need for phlebotomy over 52 weeks, according to ...

A recent clinical trial found that a new TROP2-targeted antibody-drug conjugate (ADC) showed encouraging efficacy in treating ...

Antonio Urbina, MD, the medical director for the Mount Sinai Institute for Advanced Medicine 7th Avenue clinic in New York ...

Innovations such as nurse navigators, AI-assisted prior authorizations, and community education—including rural outreach—are ...

The upcoming American Society of Hematology (ASH) 2025 meeting is poised to spotlight several pivotal developments across ...

The decision to use newer agents in relapsed/refractory follicular lymphoma is heavily influenced by the disease’s inherent ...

Panelists discuss how PCSK9 inhibitors remain underused due to access, cost, and adherence barriers.

Minimally invasive treatment and earlier surgical consideration for thymectomy led the way as potential treatments for ...

Health care is constantly evolving, and kidney health is no different. Several presentations during the IVBM event addressed ...